Skip to content

Acupuncture as a adjuvant treatment for ischemic stroke--A Multicenter, Randomized Controlled Trial

Acupuncture as a adjuvant treatment for ischemic stroke--A Multicenter, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005512
Enrollment
Unknown
Registered
2022-01-08
Start date
2022-01-08
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

acupuncture group:acupuncture

Sponsors

The first affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients 3-14 days after ischemic stroke; 2.18-75 years old Patients; 3.Clear consciousness, stable vital signs, no obvious mental retardation, Mini-Mental State Examination score in the normal range (normal boundary value: illiteracy > 17, primary school > 20, junior high school and above > 24), can cooperate with acupuncture, rehabilitation training and related basic treatment; 4.The score of modified Rankin scale (mRS) before stroke was less than 1, and the score of National Institutes of Health Stroke scale (NIHSS) after stroke was 5-15. 5.Those who understand the test and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Transient ischemic attack, reversible neurological deficit; 2.Patients confirmed by examination that the life expectancy of patients with neurological impairment caused by brain tumor, brain trauma, cerebral hemorrhage, cerebral parasite and other causes other than stroke is less than 1 year. 3.Patients with acupuncture contraindications, or stroke patients with severe primary diseases such as circulatory system, respiratory system, digestive system, urinary system, endocrine system and hematopoietic system, which can not be controlled by routine medication; patients with tumors, patients with severe infection, water, electrolyte and acid-base balance disorders, or other abnormal researchers judged to be unsuitable to participate in this trial. 4.Those with severe aphasia, sleep apnea, deafness, severe cognitive impairment and inability to communicate normally; or those who are participating in other clinical trials; 5.Patients with severe depression, anxiety, or other mental disorders; 6.Woman who is pregnant or plans to become pregnant.

Design outcomes

Primary

MeasureTime frame
mRS;

Secondary

MeasureTime frame
MBI;MAS;FMA;NIHSS;MRI;

Countries

China

Contacts

Public ContactZhuang Lixing
zhuanglixing@163.com13822287775

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026